Updated on 30th Jan 2020: A scientific summary of this one-day meeting is published.
Download

All welcome. For attendants, free registration here       https://noage100.com/contact2/

The 3rd NO-Age Symposium: NAD⁺in healthy ageing and neurodegenerative diseases – from mechanisms to clinical studies

Imagine a single, fundamental, small molecule: if our body cannot synthesise it, we will die in 20 seconds. It functions as fuel in our energy production; enabling us to climb the stairs, go hiking, and go cross-country skiing. This molecule reduces as we age, and experimental evidence from worms, flies, and mice show that it is important for longevity and the extension of healthspan. 

What molecule could this be? 

None other than the oxidised form of nicotinamide adenine dinucleotide (NAD⁺). Elucidation of the structures and functions of NAD⁺ has been linked to no less than 3 Nobel Prizes. Research in the past 10 years has revealed the role NAD⁺plays in healthy longevity, including in neuroprotection and the protection from frailty and muscle atrophy. We are testing the applications of NAD⁺in more than 4 clinical trials here in Norway: including as a treatment for Parkinson’s disease, for the accelerated-ageing disease Ataxia–telangiectasia, and to alleviate the side effects of breast cancer survivors.

In this half-day, intensive, international symposium, NO-Age members and invited speakers will share recent progress in basic research and clinical studies involving the role(s) of NAD⁺depletion in ageing and neurodegeneration. This will be the first-ever symposium dedicated to NAD⁺in Norway, and not to be missed by those keen in current topics in healthy ageing.

Det tredje NO-Age-symposiet: NAD⁺ved sunn aldring og nevrodegenerative sykdommer – fra mekanismer til kliniske studier

Se for deg et enkelt – helt fundamentalt – lite molekyl: Hvis kroppen vår ikke kan syntetisere det, vil vi dø i løpet av 20 sekunder. Det fungerer som drivstoff i energiproduksjonen vår; slik at vi kan klatre opp trapper, gå turer og langrenn. Nivået av dette molekylet reduseres mens vi eldes, og eksperimentelle bevis fra ormer, fluer og mus viser at det er viktig for lang levetid og utvidelse av «healthspan».

Hvilket molekyl kan dette være?

Ingen ringere enn den oksiderte formen av nikotinamid-adenin-dinukleotid (NAD⁺). Beskrivelse og oppklaring av strukturer og funksjoner tilhørende NAD⁺har vært knyttet til ikke mindre enn 3 Nobelpriser. Forskning de siste ti årene har avdekket hvilken rolle NAD⁺spiller for sunn levetid, blant annet for nevroproteksjon og beskyttelse mot skrøpelighet og muskelatrofi. Vi tester bruken av NAD⁺i mer enn fire kliniske studier her i Norge: Inkludert som en behandling av Parkinsons sykdom, for sykdommen Ataxia–telangiectasia (akselerert aldring), og for å lindre bivirkninger hos pasienter som har overlevd brystkreft.

I løpet av dette halvdags, intensive, internasjonale symposiet, vil NO-Age-medlemmer og inviterte foredragsholdere dele nyere fremskritt i grunnforskning og kliniske studier som involverer rollen(e) til NAD⁺utarming i aldring og nevrodegenerasjon. Dette vil være det første symposiet noensinne dedikert til NAD⁺i Norge, og ikke til å gå glipp av for de som er interessert i aktuelle temaer innen sunn aldring.

Venue:

Store Auditorium (adjacent to the 1st floor patient reception), Hovedinngang, Akershus University Hospital, 1478, Lørenskog, Norway

NAD⁺ in healthy ageing and neurodegenerative diseases: from mechanisms to clinical studies

Moderator: Evandro Fei Fang
09:00-09:05:   Welcome speech by Dr. Helge Røsjø (Research Director at Ahus, UiO)

09:05-09:50:   Key Note Dr. Charles Brenner: ‘NAD, nicotinamide riboside supplementation and aging’ (The University of Iowa)

09:50-10:10:   Dr. Hilde Nilsen: ‘NAD⁺ in DNA repair and Ataxia Telangiectasia’ (Ahus, UiO)

10:10-10:30:  Dr. Mathias Ziegler: ‘Dynamics, interactions and functional roles of subcellular NAD⁺ pools’ (UiB)

10:30-10:50: Two short talks from postdocs
Dr. Sofie Lautrup: ‘NAD⁺ in longevity and stem cell rejuvenation’ (Ahus, UiO)
Dr. Yahyah Aman: ‘NAD⁺ in neuronal resilience and Alzheimer’s disease (Ahus, UiO)

               

           

10:50-11:10:   Coffee and networking

Moderator: Hilde Nilsen
11:10-11:30:   Dr. Ole-Bjørn Tysnes: ‘NAD⁺ and amyotrophic lateral sclerosis /ALS’ (UiB & HUH)

11:30-11:50:  Dr. Charalampos Haris Tzoulis: ‘NO-PARK: a trial of nicotinamide riboside in Parkinson’s disease?’ (UiB & HUH)

11:50-12:10:   Dr. Torbjørn Omland: ‘NAD⁺ as a potential cardio-protective agent in the cardio-oncology’ (Ahus, UiO) 

12:10-12:30:   Dr. Arne Vasli Lund Søraas: ‘NR clinical trial in an age-related disease’ (OUS, UiO)

Moderator: Trygve Holmøy
12:30-13:00:   Round Table discussion on ‘Opportunities and challenges in NR-based clinical trials’ (UiO)

13:10-14:00:  Lunch for invited speakers and stuff at the Akershus University Hospital canteen (2^nd floor)

Abbreviations
UiO, University of Oslo; Ahus, Akershus University Hospital; OUS, Oslo universitetssykehus; UiB, University of Bergen; HUH, Haukeland University Hospital